TITLE

2008 - Intensive glucose control increased mortality and did not prevent cardiovascular events in type 2 diabetes

AUTHOR(S)
Montori, Victor M.; Malaga, German
PUB. DATE
September 2008
SOURCE
ACP Journal Club;9/16/2008, Vol. 149 Issue 3, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article provides an answer to the question whether intensive glucose control prevents cardiovascular events more than standard glucose control in patients suffering from type 2 diabetes and cardiovascular disease or risk factors.
ACCESSION #
34599486

 

Related Articles

  • Reducing Cardiovascular Complications of Type 2 Diabetes. Savage, Peter J.; Narayan, K.M. Venkat // Diabetes Care;Nov99, Vol. 22 Issue 11, p1769 

    Editorial. Focuses on how to reduce cardiovascular complications of type 2 diabetes. Relationship between microvascular complications and the degree of glucose control in both type 1 and 2 diabetes; Reduction of hospital utilization for cardiovascular diseases by simvastatin therapy; Economic...

  • HEALTH MATTERS. EARLY TREATMENT OF TYPE 2 DIABETES MAY REDUCE HEART DISEASE RISK.  // Today's Dietitian;Aug2015, Vol. 17 Issue 8, p55 

    No abstract available.

  • Cross-Sectional and Prospective Associations Between Proinsulin and Cardiovascular Disease Risk Factors in a Population Experiencing Rapid Cultural Transition. McKeown-Eyssen, Gail; Hanley, Anthony J. G.; Harris, Stewart B.; Hegele, Robert A.; Wolever, Thomas M.S.; Kwan, Jeremy; Connelly, Philip W.; Zinman, Bernard // Diabetes Care;Jul2001, Vol. 24 Issue 7, p1240 

    Presents a study which examined cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors using data from a sample population of type 2 diabetics in a Native Canadian community. Research design and methods; Results; Conclusions.

  • FIELD: Fenofibrate reduced CVD risk among patients with type 2 diabetes, metabolic syndrome.  // Cardiology Today;Apr2009, Vol. 12 Issue 4, p1 

    The article discusses research which found that patients with type 2 diabetes and metabolic syndrome had the greatest five-year-risk for cardiovascular disease and were likely to reap the greatest benefits from fenofibrate treatment.

  • CV Event Risk Lower with Metformin. STEIN, JILL // Renal & Urology News;Sep2011, Vol. 10 Issue 9, p1 

    The article reports on the findings of a study conducted by Alex Z. Fu and colleagues which reveals that older patients with type 2 diabetes have a significantly lower likelihood of experiencing a cardiovascular (CV) event within two years if they start a treatment with metformin.

  • Cinnamon Improves Glucose and Lipids of People With Type 2 Diabetes. Khan, Alam; Safdar, Mahpara; Khan, Mohammad Muzaffar Ali; Khattak, Khan Nawaz; Anderson, Richard A. // Diabetes Care;Dec2003, Vol. 26 Issue 12, p3215 

    OBJECTIVE — The objective of this study was to determine whether cinnamon improves blood glucose, triglyceride, total cholesterol, HDL cholesterol, and LDL cholesterol levels in people with type 2 diabetes. RESEARCH DESIGN AND METHODS — A total of 60 people with type 2 diabetes, 30...

  • Premenopausal Advantages in Postprandial Lipid Metabolism Are Lost in Women With Type 2 Diabetes. Masding, Michael G.; Stears, Anna J.; Burdge, Graham C.; Wootton, Stephen A.; Sandeman, Derek D. // Diabetes Care;Dec2003, Vol. 26 Issue 12, p3243 

    OBJECTIVE — Women with type 2 diabetes appear to lose the protection against cardiovascular disease afforded by estrogens. We examined the effects of menopausal status on postprandial clearance of dietary fat in healthy and diabetic women. RESEARCH DESIGN AND METHODS — Fasting...

  • Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients. Sacco, Michele; Pellegrini, Fabio; Roncaglioni, Maria C.; Avanzini, Fausto; Tognoni, Gianni; Nicolucci, Antonio // Diabetes Care;Dec2003, Vol. 26 Issue 12, p3264 

    OBJECTIVE — We investigated in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with type 2 diabetes. RESEARCH DESIGN AND METHODS — The Primary Prevention Project (PPP) is a randomized, open trial with a...

  • CANVAS: Canagliflozin effective as add-on therapy in type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Nov2012, Vol. 10 Issue 11, p29 

    The article reports on a study which found that canagliflozin is an effective as add-on therapy in patients with type 2 diabetes who are at elevated risk for cardiovascular disease.

  • Hypertension and Dyslipidemia in Type 2 Diabetes Mellitus in United Arab Emirates. Mathew, Elsheba; Ahmed, Maha; Hamid, Sumaira; Abdulla, Fatima; Batool, Khadija // Australasian Medical Journal;Dec2010, Vol. 3 Issue 12, p699 

    Background In United Arab Emirates (UAE), the prevalence of Diabetes Mellitus was 19.6% in 1998-2000. Co-morbidity with Hypertension (HT) and Dyslipidemia (DL) increases the probability of cardiovascular complications, and hence the study of the distribution of HT and DL in patients with type 2...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics